Bright Minds closes $175-million (U.S.) public offering

Executive Summary

• Bright Minds Biosciences Inc. has closed a public offering of 1,945,000 common shares at $90.00 per share, generating gross proceeds of $175.05 million.
• The company intends to use the net proceeds to fund future clinical trials for drug candidates targeting absence seizures, Developmental and Epileptic Encephalopathy (DEE), and Prader-Willi Syndrome, as well as initiate Phase 1 trials for BMB-105 and support general R&D and working capital.
• The underwriters have been granted a 30-day option to purchase up to an additional 291,750 common shares at the public offering price.

Key Details

• Transaction Type: Closed Public Offering of Common Shares.
• Shares Sold: 1,945,000 common shares.
• Price Per Share: $90.00 (U.S.).
• Gross Proceeds: $175.05 million (U.S.).
• Over-Allotment Option: 30-day option granted to underwriters to purchase up to 291,750 additional common shares at the public offering price, less underwriting discounts and commissions.
• Use of Proceeds:
  • Finance future clinical trials for drug candidates (absence seizures, DEE, Prader-Willi Syndrome).
  • Initiation of Phase 1 clinical drug trials for BMB-105.
  • Additional research and development work on earlier phase programs.
  • General corporate and working capital purposes.
• Joint Book-Running Managers: Jefferies, TD Cowen, Piper Sandler & Co., and Cantor.
• Regulatory Filing: Shelf registration statement on Form F-3 with the SEC, declared effective on Sept. 2, 2025.